Metformin: the safest hypoglycaemic agent in chronic kidney disease?
Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. Its prescription in patients with renal impairment is limited by concerns relating to the theoretical risk of lactic acidosis, a fear which is perpetuated by numerous case reports in which it is implicated. Critical review of this literature calls into question the validity of these claims, with metformin usually acti...Expand abstract
- Publisher copy:
- Copyright date:
If you are the owner of this record, you can report an update to it here: Report update to this record